Press Releases

First Berlin Equity Research on 01/21/2025 initiated coverage on Lisata Therapeutics, Inc. (ISIN: US1280583022/ Bloomberg: LSTA US). Analyst Christian Orquera placed a BUY rating on the stock, with a USD 15.00 price target. A summary of the report is available below.

BASKING RIDGE, N.J., Jan. 15, 2025 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J.